DOXOFYLLINE 400mg. IP

A newer generation xanthine molecule with both bronchodilating and anti-inflammatory activities. (Mario Cazzola, 2020) Possesses a wider therapeutic window over conventional xanthines such as theophylline in the treatment of lung diseases. (Page, 2010) A potent bronchodilator medicine that treats blockage, swelling, shortness of breath, associated with asthma, and other obstructive diseases of the lungs. Effective and well-tolerated therapy in asthmatic patients. (Luigino Calzetta, 2020) An antibronchospastic drug that offers safe and effective treatment of obstructive lung disease. Demonstrates significant anti-inflammatory activity in the lung with significant steroid-sparing activity. Contributes improvement to the pulmonary function tests as well as clinical symptoms in both asthma and COPD patients. (Dushyant Lal, 2015) Significantly more effective than theophylline in reducing daily asthma events. (Paola Rogliani, 2019) Relieves the airway obstruction and displays a better safety profile than theophylline. (Marc F Goldstein, 2002) Provides statistically significant reduction in the asthma attack rate and the need for rescue salbutamol inhalation in patients with bronchial asthma. (Sami Manzoor Margay, 2015) A good alternative to theophylline in the treatment of reversible chronic airway obstruction. (G Melillo, 1989)